Provided by Tiger Trade Technology Pte. Ltd.

Immutep

4.20
-0.3400-7.49%
Volume:45.73K
Turnover:194.23K
Market Cap:30.91M
PE:-0.56
High:4.53
Open:4.49
Low:4.17
Close:4.54
52wk High:70.60
52wk Low:4.17
Shares:7.36M
Float Shares:6.90M
Volume Ratio:1.70
T/O Rate:0.66%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.4575
EPS(LYR):-7.4576
ROE:-77.31%
ROA:-42.45%
PB:0.72
PE(LYR):-0.56

Loading ...

Immutep Director Increases Shareholding Through Performance Rights Exercise

TIPRANKS
·
Oct 01

Immutep Applies to Quote New Ordinary Shares on ASX

TIPRANKS
·
Oct 01

Immutep Receives ~A$0.86 Million R&D Tax Incentive

GlobeNewswire
·
Sep 30

Immutep Ltd trading halted, news pending

TIPRANKS
·
Sep 26

NASDAQ Trade Halt Halt News Pending at 07:50 Pm

Reuters
·
Sep 26

Change to American Depositary Share Ratio

GlobeNewswire
·
Sep 21

Immutep Gets a New Bull at Jefferies

Dow Jones
·
Sep 15

Immutep provides update on development strategy for eftilagimod alfa

TIPRANKS
·
Sep 11

Immutep Outlines Focused Development Strategy for Eftilagimod Alfa (“efti”)

GlobeNewswire
·
Sep 11

Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026

GlobeNewswire
·
Jul 24

Immutep Granted New US Patent for Cancer Treatment Methods

MT Newswires Live
·
Jul 14

Immutep granted new patent for eftilagimod alfa combination

TIPRANKS
·
Jul 14

Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor

GlobeNewswire
·
Jul 14

Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004

GlobeNewswire
·
Jul 13

Immutep Shares Rise After Maxim Group Upgrade

MT Newswires Live
·
Jun 18

Immutep Raised to Buy From Hold by Maxim Group

Dow Jones
·
Jun 17

Maxim Group Upgrades Immutep to Buy From Hold, $1.50 Price Target

MT Newswires Live
·
Jun 17

Immutep Ltd : Maxim Group Raises to Buy From Hold

THOMSON REUTERS
·
Jun 17

Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026

GlobeNewswire
·
Jun 04

Systemic immune activation with eftilagimod alfa associated with statistically significant increased overall survival in late-stage cancer patients

GlobeNewswire
·
May 28